ProQR Therapeutics (PRQR) Receivables (2022 - 2026)

ProQR Therapeutics has reported Receivables for 4 years, with the latest figure at $5.5 million in Q1 2026.

• Quarterly Receivables changed N/A year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (changed N/A YoY) and the FY2025 annual result came in at $8.3 million, up 69.1% from the prior year.
• Receivables fell to $5.5 million in Q1 2026 per PRQR's latest filing, from $8.3 million in the prior quarter.
• Over five years, Receivables peaked at $57.8 million in Q4 2022 and troughed at $4.9 million in Q4 2024.
• A 4-year average of $19.1 million and a median of $6.9 million in 2026 frame the typical range for Receivables.
• The widest YoY moves for Receivables: up 69.1% in 2025, down 69.1% in 2025.
• Over 4 years, Receivables stood at $57.8 million in 2022, then tumbled by 91.53% to $4.9 million in 2024, then jumped by 69.1% to $8.3 million in 2025, then plunged by 33.23% to $5.5 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $5.5 million, $8.3 million, and $4.9 million for Q1 2026, Q4 2025, and Q4 2024 respectively.